Biotech company Chimerix sets terms for $85 million IPO

By
A A A

Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, announced terms for its IPO on Monday. The Durham, NC-based company plans to raise $85 million by offering 6.1 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chimerix would command a market value of $325 million.

Chimerix, which booked $34 million in sales for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol CMRX. Chimerix initially filed confidentially on 1/30/2013. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CMRX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

55,414,702
  • $15.38 ▼ 0.39%
38,503,210
  • $66.34 ▲ 2.26%
36,466,704
  • $8.36 ▼ 9.52%
35,253,294
  • $26.55 ▲ 1.34%
32,752,347
  • $6.55 ▲ 1.87%
31,778,001
  • $95.22 ▲ 0.19%
28,396,556
  • $51.49 ▼ 0.62%
23,800,987
  • $42.09 ▲ 0.97%
As of 7/11/2014, 04:03 PM